Skip to content
2000
image of The Effects of Resveratrol on Menopausal Cardio-metabolic Changes: A Systematic Review

Abstract

Introduction

Menopause is known as a stage in a woman's natural life cycle in which menstrual periods permanently stop with developing age. This review aims to review the modulating mechanistic effects of resveratrol (RSV) on cardiometabolic changes associated with menopause.

Methods

To identify published studies before January 12, 2025, a comprehensive search was conducted across various electronic databases, such as Web of Science, PubMed/MEDLINE, Embase, Scopus, and the Cochrane Library. Based on the study's objectives, two reviewers independently performed data extraction to ensure accuracy and reduce bias. The extracted data were subsequently reviewed.

Results

RSV has reductive effects on blood pressure, improves endothelial function, and enhances insulin-stimulated glucose uptake. It also decreases fasting blood glucose levels, insulin levels, total cholesterol, triglycerides, and adipocyte hypertrophy. Increased estradiol levels correlate with improved cerebrovascular function and enhanced neurovascular coupling. However, the effects on body weight, body mass index (BMI), and lipid metabolism are inconsistent; some studies reported reductions in fat volume and changes in thermogenesis-related gene expression. Moreover, total antioxidant capacity (TAC) and malondialdehyde (MDA) levels increase. While RSV demonstrates potential benefits for vascular function and metabolic regulation, further research is necessary to determine its long-term efficacy.

Discussion

The findings align with existing evidence on RSV’s vascular and metabolic benefits, underscoring its complementary therapeutic potential. Limitations, like bioavailability, differences in patient characteristics, and inconsistent lipid outcomes, call for standardized and long-term studies.

Conclusion

RSV, as a phytoestrogen, increases estrogen levels in the intervention groups. RSV shows potential effects in modulating the most studied menopausal cardio-metabolic changes.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chddt/10.2174/011871529X398468250910225946
2025-09-23
2025-12-16

  • From This Site

    /content/journals/chddt/10.2174/011871529X398468250910225946
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Luo Z. Yin F. Wang X. Kong L. Progress in approved drugs from natural product resources. Chin. J. Nat. Med. 2024 22 3 195 211 10.1016/S1875‑5364(24)60582‑0 38553188
    [Google Scholar]
  2. Santoro N. Roeca C. Peters B.A. Neal-Perry G. The menopause transition: Signs, symptoms, and management options. J. Clin. Endocrinol. Metab. 2021 106 1 1 15 10.1210/clinem/dgaa764 33095879
    [Google Scholar]
  3. Chen Q. Zhang Y. Li S. Chen S. Lin X. Li C. Asakawa T. Mechanisms underlying the prevention and treatment of cholelithiasis using traditional chinese medicine. Evid. Based Complement. Alternat. Med. 2019 2019 1 9 10.1155/2019/2536452 31316569
    [Google Scholar]
  4. Lee E. Anselmo M. Tahsin C.T. Vanden Noven M. Stokes W. Carter J.R. Keller-Ross M.L. Vasomotor symptoms of menopause, autonomic dysfunction, and cardiovascular disease. Am. J. Physiol. Heart Circ. Physiol. 2022 323 6 H1270 H1280 10.1152/ajpheart.00477.2022 36367692
    [Google Scholar]
  5. Conde D.M. Verdade R.C. Valadares A.L.R. Mella L.F.B. Pedro A.O. Costa-Paiva L. Menopause and cognitive impairment: A narrative review of current knowledge. World J. Psychiatry 2021 11 8 412 428 10.5498/wjp.v11.i8.412 34513605
    [Google Scholar]
  6. Ou Y.J. Lee J.I. Huang S.P. Chen S.C. Geng J.H. Su C.H. Association between Menopause, Postmenopausal Hormone Therapy and Metabolic Syndrome. J. Clin. Med. 2023 12 13 4435 10.3390/jcm12134435 37445470
    [Google Scholar]
  7. Ko S.H. Kim H.S. Menopause-associated lipid metabolic disorders and foods beneficial for postmenopausal women. Nutrients 2020 12 1 202 10.3390/nu12010202 31941004
    [Google Scholar]
  8. Paduszyńska A. Banach M. Maciejewski M. Dąbrowa M. Bielecka-Dąbrowa A. The outcomes of hypertension treatment depending on gender in patients over 40 years of age. Przegl. Menopauz. 2020 19 4 174 178 10.5114/pm.2020.101947 33488328
    [Google Scholar]
  9. Yerra A.K. Bala S. Yalamanchili R.K. Bandaru R.K. Mavoori A. Menopause-related quality of life among urban women of hyderabad, india. J Midlife Health 2021 12 2 161 167 10.4103/jmh.jmh_272_20 34526752
    [Google Scholar]
  10. Baral S. Kaphle H.P. Health-related quality of life among menopausal women: A cross-sectional study from Pokhara, Nepal. PLoS One 2023 18 1 0280632 10.1371/journal.pone.0280632 36662806
    [Google Scholar]
  11. Ryczkowska K. Adach W. Janikowski K. Banach M. Bielecka-Dabrowa A. Menopause and women’s cardiovascular health: Is it really an obvious relationship? Arch. Med. Sci. 2023 19 2 458 466 10.5114/aoms/157308 37034510
    [Google Scholar]
  12. Stevenson J.C. Tsiligiannis S. Panay N. Cardiovascular risk in perimenopausal women. Curr. Vasc. Pharmacol. 2019 17 6 591 594 10.2174/1570161116666181002145340 30280667
    [Google Scholar]
  13. Magraith K. Jang C. Management of menopause. Aust. Prescr. 2023 46 3 48 53 10.18773/austprescr.2023.014 38053812
    [Google Scholar]
  14. Shapiro M. Menopause practice: A clinician’s guide. Can. Fam. Physician 2012 58 9 989
    [Google Scholar]
  15. Miller V.M. Black D.M. Brinton E.A. Budoff M.J. Cedars M.I. Hodis H.N. Lobo R.A. Manson J.E. Merriam G.R. Naftolin F. Santoro N. Taylor H.S. Harman S.M. Using basic science to design a clinical trial: Baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J. Cardiovasc. Transl. Res. 2009 2 3 228 239 10.1007/s12265‑009‑9104‑y 19668346
    [Google Scholar]
  16. Wang H. Chen Y. Wang L. Liu Q. Yang S. Wang C. Advancing herbal medicine: Enhancing product quality and safety through robust quality control practices. Front. Pharmacol. 2023 14 1265178 10.3389/fphar.2023.1265178 37818188
    [Google Scholar]
  17. Hashemi N. Jafarzadeh L. Altememy D. Driss F. Validi M. Khosravian P. Study of antibacterial effect of the hydroalchoholic extract of Teucrium polium against clinical strain of Gardnerella vaginalis in vitro. Mater. Today Proc. 2022 60 1502 1506 10.1016/j.matpr.2021.12.013
    [Google Scholar]
  18. Habibi Ghahfarrokhi S. Reisi R. Effects of medicinal herbs on osteoporosis: A systematic review based on clinical trials. Shahrekord Univ. Med. Sci. J. 2019 21 5 229 236 10.34172/jsums.2019.40
    [Google Scholar]
  19. Habibi Ghahfarrokhi S. Heidari-Soureshjani S. Sherwin C.M.T. Azadegan-Dehkordi Z. Efficacy and mechanisms of Silybum Marianum, silymarin, and silibinin on rheumatoid arthritis and osteoarthritis symptoms: A systematic review. Curr. Rheumatol. Rev. 2024 20 4 414 425 10.2174/0115733971266397231122080247 38314596
    [Google Scholar]
  20. Li X. Phillips F.M. An H.S. Ellman M. Thonar E.J. Wu W. Park D. Im H.J. The action of resveratrol, a phytoestrogen found in grapes, on the intervertebral disc. Spine 2008 33 24 2586 2595 10.1097/BRS.0b013e3181883883 19011540
    [Google Scholar]
  21. Maharani B.T. Rosyidah W. Exploring resveratrol intervention in managing menopausal symptoms: A comprehensive systematic review of clinical trials. Asian J. Med. Sci. 2024 3 2 171 182
    [Google Scholar]
  22. Davinelli S. Scapagnini G. Marzatico F. Nobile V. Ferrara N. Corbi G. Influence of equol and resveratrol supplementation on health-related quality of life in menopausal women: A randomized, placebo-controlled study. Maturitas 2017 96 77 83 10.1016/j.maturitas.2016.11.016 28041599
    [Google Scholar]
  23. Rodrigues Uggioni M.L. Ronsani L. Motta S. Denoni Júnior J.C. Marçal F. Dagostin Ferraz S. Rosa M.I. Colonetti T. Effects of resveratrol on the lipid profile of post-menopause women: Systematic review and meta-analysis. Nutr. Metab. Cardiovasc. Dis. 2025 35 4 103827 10.1016/j.numecd.2024.103827 39799097
    [Google Scholar]
  24. Vors C. Couillard C. Paradis M.E. Gigleux I. Marin J. Vohl M.C. Couture P. Lamarche B. Supplementation with resveratrol and curcumin does not affect the inflammatory response to a high-fat meal in older adults with abdominal obesity: A randomized, placebo-controlled crossover trial. J. Nutr. 2018 148 3 379 388 10.1093/jn/nxx072 29546309
    [Google Scholar]
  25. Schardt C. Adams M.B. Owens T. Keitz S. Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med. Inform. Decis. Mak. 2007 7 1 16 10.1186/1472‑6947‑7‑16 17573961
    [Google Scholar]
  26. Hooijmans C.R. Rovers M.M. de Vries R.B.M. Leenaars M. Ritskes-Hoitinga M. Langendam M.W. SYRCLE’s risk of bias tool for animal studies. BMC Med. Res. Methodol. 2014 14 1 43 10.1186/1471‑2288‑14‑43 24667063
    [Google Scholar]
  27. Sterne J.A.C. Savović J. Page M.J. Elbers R.G. Blencowe N.S. Boutron I. Cates C.J. Cheng H.Y. Corbett M.S. Eldridge S.M. Emberson J.R. Hernán M.A. Hopewell S. Hróbjartsson A. Junqueira D.R. Jüni P. Kirkham J.J. Lasserson T. Li T. McAleenan A. Reeves B.C. Shepperd S. Shrier I. Stewart L.A. Tilling K. White I.R. Whiting P.F. Higgins J.P.T. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 2019 366 l4898 10.1136/bmj.l4898 31462531
    [Google Scholar]
  28. McGuinness L.A. Higgins J.P.T. Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessments. Res. Synth. Methods 2021 12 1 55 61 10.1002/jrsm.1411 32336025
    [Google Scholar]
  29. Page M.J. McKenzie J.E. Bossuyt P.M. Boutron I. Hoffmann T.C. Mulrow C.D. Shamseer L. Tetzlaff J.M. Akl E.A. Brennan S.E. Chou R. Glanville J. Grimshaw J.M. Hróbjartsson A. Lalu M.M. Li T. Loder E.W. Mayo-Wilson E. McDonald S. McGuinness L.A. Stewart L.A. Thomas J. Tricco A.C. Welch V.A. Whiting P. Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021 372 71 n71 10.1136/bmj.n71 33782057
    [Google Scholar]
  30. The effects of resveratrol and acute exercise on endothelial function in postmenopausal women. NCT Patent 02256540 2014
  31. Effect of resveratrol and vitamin C on insulin resistance among postmenopausal women. NCT Patent 03090997 2017
  32. Effects of resveratrol supplements on vascular health in postmenopausal women. NCT Patent 01564381 2012
  33. Kim M.H. Bae Y.J. Dietary isoflavone intake, urinary isoflavone level, and their relationship with metabolic syndrome diagnostic components in korean postmenopausal women. Clin. Nutr. Res. 2013 2 1 59 66 10.7762/cnr.2013.2.1.59 23429755
    [Google Scholar]
  34. Zern T.L. West K.L. Fernandez M.L. Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs. J. Nutr. 2003 133 7 2268 2272 10.1093/jn/133.7.2268 12840191
    [Google Scholar]
  35. Zern T.L. Wood R.J. Greene C. West K.L. Liu Y. Aggarwal D. Shachter N.S. Fernandez M.L. Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J. Nutr. 2005 135 8 1911 1917 10.1093/jn/135.8.1911 16046716
    [Google Scholar]
  36. Bhavnani B.R. Cecutti A. Gerulath A. Woolever A.C. Berco M. Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women. Menopause 2018 25 11 1214 1223 10.1097/GME.0000000000001222 30358716
    [Google Scholar]
  37. Mizutani K. Ikeda K. Kawai Y. Yamori Y. Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. J. Nutr. Sci. Vitaminol. 2000 46 2 78 83 10.3177/jnsv.46.78 10885794
    [Google Scholar]
  38. Wong R.H.X. Howe P.R.C. Buckley J.D. Coates A.M. Kunz I. Berry N.M. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr. Metab. Cardiovasc. Dis. 2011 21 11 851 856 10.1016/j.numecd.2010.03.003 20674311
    [Google Scholar]
  39. Tan Z. Zhou L.J. Mu P.W. Liu S.P. Chen S.J. Fu X.D. Wang T.H. Caveolin-3 is involved in the protection of resveratrol against high-fat-diet-induced insulin resistance by promoting GLUT4 translocation to the plasma membrane in skeletal muscle of ovariectomized rats. J. Nutr. Biochem. 2012 23 12 1716 1724 10.1016/j.jnutbio.2011.12.003 22569348
    [Google Scholar]
  40. Yoshino J. Conte C. Fontana L. Mittendorfer B. Imai S. Schechtman K.B. Gu C. Kunz I. Fanelli F.R. Patterson B.W. Klein S. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012 16 5 658 664 10.1016/j.cmet.2012.09.015 23102619
    [Google Scholar]
  41. Majumdar A.S. Joshi P.A. Giri P.R. Resveratrol attenuated smokeless tobacco–induced vascular and metabolic complications in ovariectomized rats. Menopause 2013 20 8 869 876 10.1097/GME.0b013e31827fdda4 23884055
    [Google Scholar]
  42. Chow H.H.S. Garland L.L. Heckman-Stoddard B.M. Hsu C.H. Butler V.D. Cordova C.A. Chew W.M. Cornelison T.L. A pilot clinical study of resveratrol in postmenopausal women with high body mass index: Effects on systemic sex steroid hormones. J. Transl. Med. 2014 12 1 223 10.1186/s12967‑014‑0223‑0 25115686
    [Google Scholar]
  43. Majumdar A.S. Giri P.R. Pai S.A. Resveratrol- and melatonin-abated ovariectomy and fructose diet–induced obesity and metabolic alterations in female rats. Menopause 2014 21 8 876 885 10.1097/GME.0000000000000187 24473532
    [Google Scholar]
  44. Miller C.N. Yang J.Y. Avra T. Ambati S. Della-Fera M.A. Rayalam S. Baile C.A. A dietary phytochemical blend prevents liver damage associated with adipose tissue mobilization in ovariectomized rats. Obesity 2015 23 1 112 119 10.1002/oby.20907 25451038
    [Google Scholar]
  45. Jeong S.I. Shin J.A. Cho S. Kim H.W. Lee J.Y. Kang J.L. Park E.M. Resveratrol attenuates peripheral and brain inflammation and reduces ischemic brain injury in aged female mice. Neurobiol. Aging 2016 44 74 84 10.1016/j.neurobiolaging.2016.04.007 27318135
    [Google Scholar]
  46. Myasoedova V. Kirichenko T. Melnichenko A. Orekhova V. Ravani A. Poggio P. Sobenin I. Bobryshev Y. Orekhov A. Anti-Atherosclerotic Effects of a Phytoestrogen-Rich Herbal Preparation in Postmenopausal Women. Int. J. Mol. Sci. 2016 17 8 1318 10.3390/ijms17081318 27529226
    [Google Scholar]
  47. Evans H. Howe P. Wong R. Effects of resveratrol on cognitive performance, mood and cerebrovascular function in post-menopausal women; a 14-week randomised placebo-controlled intervention trial. Nutrients 2017 9 1 27 10.3390/nu9010027 28054939
    [Google Scholar]
  48. Fabricio V. Oishi J.C. Biffe B.G. Ruffoni L.D.G. Silva K.A. Nonaka K.O. Rodrigues G.J. Resveratrol treatment normalizes the endothelial function and blood pressure in ovariectomized rats. Arq. Bras. Cardiol. 2017 108 2 116 121 10.5935/abc.20170012 28327868
    [Google Scholar]
  49. Sharma R. Sharma N.K. Thungapathra M. Resveratrol regulates body weight in healthy and ovariectomized rats. Nutr. Metab. 2017 14 1 30 10.1186/s12986‑017‑0183‑5 28413432
    [Google Scholar]
  50. Li Y. Huang J. Yan Y. Liang J. Liang Q. Lu Y. Zhao L. Li H. Preventative effects of resveratrol and estradiol on streptozotocin-induced diabetes in ovariectomized mice and the related mechanisms. PLoS One 2018 13 10 0204499 10.1371/journal.pone.0204499 30273360
    [Google Scholar]
  51. Rossi E.L. Khatib S.A. Doerstling S.S. Bowers L.W. Pruski M. Ford N.A. Glickman R.D. Niu M. Yang P. Cui Z. DiGiovanni J. Hursting S.D. Resveratrol inhibits obesity‐associated adipose tissue dysfunction and tumor growth in a mouse model of postmenopausal claudin‐low breast cancer. Mol. Carcinog. 2018 57 3 393 407 10.1002/mc.22763 29197120
    [Google Scholar]
  52. Li B. Xiao X. Miao Y. Guo L. Zhen J. Li X. Jiang B. Hu Z. Resveratrol alleviates obesity-associated podocyte injury in ovariectomized obese rats. Exp. Ther. Med. 2020 19 1 123 130 31853281
    [Google Scholar]
  53. Ozemek C. Hildreth K.L. Blatchford P.J. Effects of resveratrol or estradiol on postexercise endothelial function in estrogen-deficient postmenopausal women. J. Appl. Physiol. 2020 128 4 739 747 10.1152/japplphysiol.00488.2019
    [Google Scholar]
  54. Thaung Zaw J.J. Howe P.R.C. Wong R.H.X. Sustained cerebrovascular and cognitive benefits of resveratrol in postmenopausal Women. Nutrients 2020 12 3 828 10.3390/nu12030828 32244933
    [Google Scholar]
  55. Thaung Zaw J.J. Howe P.R.C. Wong R.H.X. Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study. Clin. Nutr. 2021 40 3 820 829 10.1016/j.clnu.2020.08.025 32900519
    [Google Scholar]
  56. Zaychenko G. Stryga O. Sinitsyna O. Doroshenko A. Sulaieva O. Falalyeyeva T. Kobyliak N. Resveratrol effects on the reproductive system in ovariectomized rats: Deciphering possible mechanisms. Molecules 2022 27 15 4916 10.3390/molecules27154916 35956866
    [Google Scholar]
  57. Arisawa K. Kaneko M. Matsuoka A. Ozawa N. Kawawa R. Ishikawa T. Ichi I. Fujiwara Y. Piceatannol prevents obesity and fat accumulation caused by estrogen deficiency in female mice by promoting lipolysis. Nutrients 2023 15 6 1374 10.3390/nu15061374 36986104
    [Google Scholar]
  58. Jing Y. Hu T. Yuan J. Liu Z. Tao M. Ou M. Cheng X. Cheng W. Yi Y. Xiong Q. Resveratrol protects against postmenopausal atherosclerosis progression through reducing PCSK9 expression via the regulation of the ERα-mediated signaling pathway. Biochem. Pharmacol. 2023 211 115541 10.1016/j.bcp.2023.115541 37030661
    [Google Scholar]
  59. Montoya-Estrada A. García-Cortés A.Y. Romo-Yañez J. Ortiz-Luna G.F. Arellano-Eguiluz A. Belmont-Gómez A. Lopéz-Ugalde V. León-Reyes G. Flores-Pliego A. Espejel-Nuñez A. Solis-Paredes J.M. Reyes-Muñoz E. The administration of resveratrol and vitamin c reduces oxidative stress in postmenopausal women-a pilot randomized clinical trial. Nutrients 2024 16 21 3775 10.3390/nu16213775 39519608
    [Google Scholar]
  60. Viana F.S. Pereira J.A. Crespo T.S. Reis Amaro L.B. Rocha E.F. Fereira A.C. Lelis D.F. Baldo T.O.F. Baldo M.P. Santos S.H.S. Andrade J.M.O. Oral supplementation with resveratrol improves hormonal profile and increases expression of genes associated with thermogenesis in oophorectomy mice. Mol. Cell. Endocrinol. 2024 591 112268 10.1016/j.mce.2024.112268 38735622
    [Google Scholar]
  61. 2004 Resveratrol Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Resveratrol
  62. Roy A. Roy M. Gacem A. Datta S. Zeyaullah M. Muzammil K. Farghaly T.A. Abdellattif M.H. Yadav K.K. Simal-Gandara J. Role of bioactive compounds in the treatment of hepatitis: A review. Front. Pharmacol. 2022 13 1051751 10.3389/fphar.2022.1051751 36618936
    [Google Scholar]
  63. Burns J. Yokota T. Ashihara H. Lean M.E.J. Crozier A. Plant foods and herbal sources of resveratrol. J. Agric. Food Chem. 2002 50 11 3337 3340 10.1021/jf0112973 12010007
    [Google Scholar]
  64. Bohara R.A. Tabassum N. Singh M.P. Gigli G. Ragusa A. Leporatti S. Recent overview of resveratrol’s beneficial effects and its nano-delivery systems. Molecules 2022 27 16 5154 10.3390/molecules27165154 36014390
    [Google Scholar]
  65. Brown K. Theofanous D. Britton R.G. Aburido G. Pepper C. Sri Undru S. Howells L. Resveratrol for the management of human health: How far have we come? a systematic review of resveratrol clinical trials to highlight gaps and opportunities. Int. J. Mol. Sci. 2024 25 2 747 10.3390/ijms25020747 38255828
    [Google Scholar]
  66. Kozakowski J. Gietka-Czernel M. Leszczyńska D. Majos A. Obesity in menopause – our negligence or an unfortunate inevitability? Przegl. Menopauz. 2017 2 2 61 65 10.5114/pm.2017.68594 28721132
    [Google Scholar]
  67. Opoku A.A. Abushama M. Konje J.C. Obesity and menopause. Best Pract. Res. Clin. Obstet. Gynaecol. 2023 88 102348 10.1016/j.bpobgyn.2023.102348 37244787
    [Google Scholar]
  68. Park S.K. Harlow S.D. Zheng H. Karvonen-Gutierrez C. Thurston R.C. Ruppert K. Janssen I. Randolph J.F. Association between changes in oestradiol and follicle‐stimulating hormone levels during the menopausal transition and risk of diabetes. Diabet. Med. 2017 34 4 531 538 10.1111/dme.13301 27973745
    [Google Scholar]
  69. Steiner B.M. Berry D.C. The regulation of adipose tissue health by estrogens. Front. Endocrinol. 2022 13 889923 10.3389/fendo.2022.889923 35721736
    [Google Scholar]
  70. Davis K.E.D. Neinast M. Sun K.M. Skiles W.D. Bills J.A. Zehr J. Zeve D.D. Hahner L.W. Cox D.M. Gent L. Xu Y.V. Wang Z.A. Khan S. Clegg D.J. The sexually dimorphic role of adipose and adipocyte estrogen receptors in modulating adipose tissue expansion, inflammation, and fibrosis. Mol. Metab. 2013 2 3 227 242 10.1016/j.molmet.2013.05.006 24049737
    [Google Scholar]
  71. Ventura-Clapier R. Piquereau J. Veksler V. Garnier A. Estrogens, estrogen receptors effects on cardiac and skeletal muscle mitochondria. Front. Endocrinol. 2019 10 557 10.3389/fendo.2019.00557 31474941
    [Google Scholar]
  72. Hillsley A. Chin V. Li A. McLachlan C.S. Resveratrol for weight loss in obesity: An assessment of randomized control trial designs in clinicaltrials.gov. Nutrients 2022 14 7 1424 10.3390/nu14071424 35406038
    [Google Scholar]
  73. Mongioì L.M. La Vignera S. Cannarella R. Cimino L. Compagnone M. Condorelli R.A. Calogero A.E. The role of resveratrol administration in human obesity. Int. J. Mol. Sci. 2021 22 9 4362 10.3390/ijms22094362 33921991
    [Google Scholar]
  74. Abo Alrob O. Al-Horani R.A. Altaany Z. Nusair M.B. Synergistic beneficial effects of resveratrol and diet on high-fat diet-induced obesity. Medicina (B. Aires) 2022 58 9 1301 10.3390/medicina58091301 36143977
    [Google Scholar]
  75. Aguirre L. Fernández-Quintela A. Arias N. Portillo M. Resveratrol: Anti-obesity mechanisms of action. Molecules 2014 19 11 18632 18655 10.3390/molecules191118632 25405284
    [Google Scholar]
  76. Lou Z. Huang Y. Lan Y. Li C. Chu K. Chen P. Xu W. Ma L. Zhou J. Relationship between years since menopause and lipid variation in postmenopausal women: A cross-sectional study. Medicine 2023 102 2 32684 10.1097/MD.0000000000032684 36637918
    [Google Scholar]
  77. Palmisano B.T. Zhu L. Stafford J.M. Role of Estrogens in the Regulation of Liver Lipid Metabolism. Adv. Exp. Med. Biol. 2017 1043 227 256 10.1007/978‑3‑319‑70178‑3_12 29224098
    [Google Scholar]
  78. Cao X. Liao W. Xia H. Wang S. Sun G. The effect of resveratrol on blood lipid profile: A dose-response meta-analysis of randomized controlled trials. Nutrients 2022 14 18 3755 10.3390/nu14183755 36145131
    [Google Scholar]
  79. Li Z. Liu S. Liu Q. Wang M. Haedi A.R. Zang S.S. Li J.L. Efficacy of resveratrol supplementation on lipid profile parameters: An umbrella of meta-analysis. Prostaglandins Other Lipid Mediat. 2024 175 106903 10.1016/j.prostaglandins.2024.106903 39255906
    [Google Scholar]
  80. Hou X. Xu S. Maitland-Toolan K.A. Sato K. Jiang B. Ido Y. Lan F. Walsh K. Wierzbicki M. Verbeuren T.J. Cohen R.A. Zang M. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J. Biol. Chem. 2008 283 29 20015 20026 10.1074/jbc.M802187200 18482975
    [Google Scholar]
  81. Kim M.Y. Lim J.H. Youn H.H. Hong Y.A. Yang K.S. Park H.S. Chung S. Koh S.H. Shin S.J. Choi B.S. Kim H.W. Kim Y.S. Lee J.H. Chang Y.S. Park C.W. Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK–SIRT1–PGC1α axis in db/db mice. Diabetologia 2013 56 1 204 217 10.1007/s00125‑012‑2747‑2 23090186
    [Google Scholar]
  82. Floyd Z.E. Wang Z.Q. Kilroy G. Cefalu W.T. Modulation of peroxisome proliferator–activated receptor γ stability and transcriptional activity in adipocytes by resveratrol. Metabolism 2008 57 7 S32 S38 10.1016/j.metabol.2008.04.006 18555852
    [Google Scholar]
  83. Shabalala S.C. Dludla P.V. Mabasa L. Kappo A.P. Basson A.K. Pheiffer C. Johnson R. The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. Biomed. Pharmacother. 2020 131 110785 10.1016/j.biopha.2020.110785 33152943
    [Google Scholar]
  84. Resveratrol B-R.D. Diseases C. Resveratrol and cardiovascular diseases. Nutrients 2016 8 5 250 10.3390/nu8050250
    [Google Scholar]
  85. Zhao X. An X. Yang C. Sun W. Ji H. Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. Front. Endocrinol. 2023 14 1149239 10.3389/fendo.2023.1149239 37056675
    [Google Scholar]
  86. Dilworth L. Facey A. Omoruyi F. Diabetes mellitus and its metabolic complications: The role of adipose tissues. Int. J. Mol. Sci. 2021 22 14 7644 10.3390/ijms22147644 34299261
    [Google Scholar]
  87. Wong R.H.X. Howe P.R.C. Resveratrol counteracts insulin resistance—potential role of the circulation. Nutrients 2018 10 9 1160 10.3390/nu10091160 30149556
    [Google Scholar]
  88. León D. Uribe E. Zambrano A. Salas M. Implications of resveratrol on glucose uptake and metabolism. Molecules 2017 22 3 398 10.3390/molecules22030398 28272357
    [Google Scholar]
  89. Lima R. Wofford M. Reckelhoff J.F. Hypertension in postmenopausal women. Curr. Hypertens. Rep. 2012 14 3 254 260 10.1007/s11906‑012‑0260‑0 22427070
    [Google Scholar]
  90. Li S. Tan I. Atkins E. Schutte A.E. Gnanenthiran S.R. The pathophysiology, prognosis and treatment of hypertension in females from pregnancy to post-menopause: A review. Curr. Heart Fail. Rep. 2024 21 4 322 336 10.1007/s11897‑024‑00672‑y 38861130
    [Google Scholar]
  91. Srivaratharajah K. Abramson B.L. Hypertension in menopausal women: The effect and role of estrogen. Menopause 2019 26 4 428 430 10.1097/GME.0000000000001304 30889094
    [Google Scholar]
  92. Breuss J.M. Atanasov A.G. Uhrin P. Resveratrol and its effects on the vascular system. Int. J. Mol. Sci. 2019 20 7 1523 10.3390/ijms20071523 30934670
    [Google Scholar]
  93. Gordish K.L. Beierwaltes W.H. Chronic resveratrol reverses a mild angiotensin II-induced pressor effect in a rat model. Integr. Blood Press. Control 2016 9 23 31 26869812
    [Google Scholar]
  94. Mozafari M. Nekooeian A.A. Panjeshahin M.R. Zare H.R. The effects of resveratrol in rats with simultaneous type 2 diabetes and renal hypertension: A study of antihypertensive mechanisms. Iran. J. Med. Sci. 2015 40 2 152 160 25821295
    [Google Scholar]
  95. Gal R. Deres L. Toth K. Halmosi R. Habon T. The effect of resveratrol on the cardiovascular system from molecular mechanisms to clinical results. Int. J. Mol. Sci. 2021 22 18 10152 10.3390/ijms221810152 34576315
    [Google Scholar]
  96. Prysyazhna O. Wolhuter K. Switzer C. Santos C. Yang X. Lynham S. Shah A.M. Eaton P. Burgoyne J.R. Blood pressure–lowering by the antioxidant resveratrol is counterintuitively mediated by oxidation of cGMP-dependent protein kinase. Circulation 2019 140 2 126 137 10.1161/CIRCULATIONAHA.118.037398 31116951
    [Google Scholar]
  97. Moreau K.L. Hildreth K.L. Vascular Aging across the Menopause Transition in Healthy Women. Adv. Vasc. Med. 2014 2014 1 12 10.1155/2014/204390 25984561
    [Google Scholar]
  98. Brzozowska M. Lewiński A. Changes of androgens levels in menopausal women. Przegl. Menopauz. 2020 19 4 151 154 10.5114/pm.2020.101941 33488324
    [Google Scholar]
  99. Raj A. Chakole S. Agrawal S. Gupta A. Khekade H. Prasad R. Lohakare T. Wanjari M. The impact of menopause on cardiovascular aging: A comprehensive review of androgen influences. Cureus 2023 15 8 43569 10.7759/cureus.43569 37719547
    [Google Scholar]
  100. Li H. Xia N. Hasselwander S. Daiber A. Resveratrol and Vascular Function. Int. J. Mol. Sci. 2019 20 9 2155 10.3390/ijms20092155 31052341
    [Google Scholar]
  101. Guthrie A.R. Chow H.H.S. Martinez J.A. Effects of resveratrol on drug- and carcinogen-metabolizing enzymes, implications for cancer prevention. Pharmacol. Res. Perspect. 2017 5 1 00294 10.1002/prp2.294 28596842
    [Google Scholar]
  102. Detampel P. Beck M. Krähenbühl S. Huwyler J. Drug interaction potential of resveratrol. Drug Metab. Rev. 2012 44 3 253 265 10.3109/03602532.2012.700715 22788578
    [Google Scholar]
  103. Korobkova E.A. Effect of natural polyphenols on CYP metabolism: Implications for diseases. Chem. Res. Toxicol. 2015 28 7 1359 1390 10.1021/acs.chemrestox.5b00121 26042469
    [Google Scholar]
  104. Shaito A. Posadino A.M. Younes N. Hasan H. Halabi S. Alhababi D. Al-Mohannadi A. Abdel-Rahman W.M. Eid A.H. Nasrallah G.K. Pintus G. Potential adverse effects of resveratrol: A literature review. Int. J. Mol. Sci. 2020 21 6 2084 10.3390/ijms21062084 32197410
    [Google Scholar]
/content/journals/chddt/10.2174/011871529X398468250910225946
Loading
The Effects of Resveratrol on Menopausal Cardio-metabolic Changes: A Systematic Review
Bentham Science Publishers ; https://doi.org/10.2174/011871529X398468250910225946
/content/journals/chddt/10.2174/011871529X398468250910225946
/content/journals/chddt/10.2174/011871529X398468250910225946
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keywords: menopause ; insulin ; obesity ; Resveratrol ; hypertension ; phytoestrogens

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test